Browsing Category
Pharma Industry News
4724 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
What rademikibart Phase 3 data could mean for Connect Biopharma’s immunology strategy (NASDAQ: CNTB)
Connect Biopharma’s rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what it means for biologic competition and Connect Biopharma strategy.
United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
United Therapeutics reports strong Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis. Discover why this inhaled therapy could reshape treatment.
Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?
Could subcutaneous PD-1 therapy reshape cancer treatment in China? Explore Junshi Biosciences’ toripalimab filing and its impact on oncology logistics.
The hidden problem with GLP-1 weight loss and Veru Inc.’s bet to fix it (NASDAQ: VERU)
Veru Inc. launches the Phase 2b PLATEAU trial combining enobosarm with semaglutide. Discover what this could mean for the $100B obesity drug market.
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.
Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy?
EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden.
GSK to sell linerixibat rights to Alfasigma for up to $690m as rare liver disease drug nears FDA approval
GSK and Alfasigma agree worldwide licence for linerixibat, a rare liver disease itch drug nearing FDA approval. Deal worth up to $690 million. Read more.
CSL (ASX:CSL) breaks ground on $1.5bn Kankakee plasma plant expansion, betting patented Horizon 2 technology can widen its immunoglobulin lead
CSL (ASX:CSL) breaks ground on a $1.5B Kankakee plasma plant expansion using patented Horizon 2 yield tech. Read the full strategic analysis.
Can RNA interference expand beyond rare diseases through Tenaya–Alnylam cardiovascular research? (NASDAQ: ALNY, NASDAQ: TNYA)
Tenaya Therapeutics and Alnylam Pharmaceuticals partner to discover RNAi drug targets for cardiovascular disease. Read what this biotech deal could mean.
How petrelintide’s tolerability profile could reshape patient adherence in obesity pharmacotherapy
Can petrelintide improve adherence in obesity treatment? Discover how Zealand Pharma’s therapy could reshape the weight-loss drug market.